Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

How do vaccinated people spread Delta? What the science says.

13 Aug, 2021 | 09:55h | UTC

How do vaccinated people spread Delta? What the science says – Nature

 

Opinion: Making vaccines available to other countries before offering domestic booster vaccinations.

13 Aug, 2021 | 09:48h | UTC

Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations – JAMA

 

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

13 Aug, 2021 | 09:58h | UTC

Could This Be Our First Effective, Inexpensive, Widely Available Outpatient Treatment for COVID-19? – HIV and ID Observations

Related: Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

13 Aug, 2021 | 10:01h | UTC

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison – American Family Physician

Related:

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

 

Opinion: Time for a smart approach to boosters.

13 Aug, 2021 | 09:51h | UTC

Time for a Smart Approach to Boosters – Think Global Health

 

Antibody response to COVID-19 vaccination in adults with hematologic malignant disease.

13 Aug, 2021 | 09:47h | UTC

Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease – JAMA Oncology

 

Commentary on Twitter

 

How COVID-19 will change the management of other respiratory viral infections.

13 Aug, 2021 | 09:52h | UTC

How COVID-19 will change the management of other respiratory viral infections – Intensive Care Medicine

 

Commentary on Twitter

 

RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.

12 Aug, 2021 | 09:56h | UTC

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients – New England Journal of Medicine

Editorial: Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients

Related:

Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients.

Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

[Preprint] 3rd AstraZeneca shot gives strong immunity.

 

Commentaries on Twitter

https://twitter.com/hildabast/status/1425576801850433537

 

RCT: Evaluation of Moderna mRNA vaccine in adolescents.

12 Aug, 2021 | 09:58h | UTC

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine

Related:

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

RCT: Pfizer-BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – mainly transient mild-to-moderate reactogenicity was frequently observed, such as injection-site pain (in 79 to 86% of participants), fatigue (in 60 to 66%), and headache (in 55 to 65%).

 

Commentaries on Twitter

 

Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time.

12 Aug, 2021 | 09:54h | UTC

Moderna may be superior to Pfizer against delta variant — breakthrough odds rise with time – CNBC

Original Study 1 (preprint): Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence – medRxiv

Original Study 2 (preprint): Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers – medRxiv

Related:

Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

 

[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna.

12 Aug, 2021 | 09:53h | UTC

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar – medRxiv

Related:

Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

 

Commentary on Twitter

 

WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs.

12 Aug, 2021 | 09:02h | UTC

WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs – World Health Organization

Commentary:

WHO-led Trial Will Test Malaria and Cancer Medicines Against COVID-19 – Health Policy Watch

Related:

A giant trial of COVID-19 treatments organized by the WHO is restarting. Here are the drugs it’s betting on.

WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.

 

Commentary on Twitter (thread – click for more)

 

Video: Frequently Asked COVID-19 Vaccine Questions – August 2021 Update.

12 Aug, 2021 | 08:59h | UTC

Frequently Asked COVID-19 Vaccine Questions – August 2021 Update – JAMA

 

Vaccination: Effectiveness versus Efficacy.

12 Aug, 2021 | 09:01h | UTC

Vaccination: Effectiveness versus Efficacy – by Luis Correa, MD

 

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

12 Aug, 2021 | 09:05h | UTC

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis – New England Journal of Medicine

Commentary: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD

Related:

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Commentary on Twitter

 

RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.

12 Aug, 2021 | 08:51h | UTC

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women – New England Journal of Medicine

 

Vaccines given in last 20 years could prevent 50 million deaths in LMICs.

12 Aug, 2021 | 08:43h | UTC

Vaccines given in last 20 years could prevent 50 million deaths in LMICs – Imperial College London

Original study: Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world – eLife

 

Cutaneous manifestations of infections: an update for general physicians.

12 Aug, 2021 | 08:36h | UTC

Cutaneous manifestations of infections: an update for general physicians – Clinical Medicine Journal

 

M-A: Asymptomatic SARS-CoV-2 infection – “we estimate that the percentage of infections that never developed clinical symptoms, and thus were truly asymptomatic, was 35.1%”.

11 Aug, 2021 | 08:49h | UTC

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis – Proceedings of the National Academy of Sciences

 

Commentary on Twitter

 

PRINCIPLE RCT: Inhaled budesonide improves time to recovery from COVID-19 in people at high risk of complications in the community.

11 Aug, 2021 | 08:52h | UTC

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Invited Commentary: The use of inhaled corticosteroids in early-stage COVID-19

 

WHO Guidance for surveillance of SARS-CoV-2 variants.

11 Aug, 2021 | 08:50h | UTC

Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021 – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

M-A: More than 50 long-term effects of COVID-19.

11 Aug, 2021 | 08:47h | UTC

More than 50 long-term effects of COVID-19: a systematic review and meta-analysis – Scientific Reports

Related:

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Cohort study: Risk factors for long covid in previously hospitalized children.

Viewpoint: The road to addressing Long Covid.

Review: Long covid—mechanisms, risk factors, and management.

Review: Symptoms, complications and management of long COVID.

Long Covid: fatigue, post-exertional malaise, and cognitive dysfunction are the most common symptoms, according to an international survey.

Studies elucidate poorly understood long COVID.

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.

[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.

Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.

Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.

[Preprint] Long Covid: Third of people infected have long term symptoms.

Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.

Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.

Perspective | The four most urgent questions about long COVID.

Systematic review: Frequency, signs and symptoms, and criteria adopted for long COVID-19.

Report: 376,000 people in UK have had long Covid symptoms for at least a year.

Systematic review of 45 studies including 9751 participants, most of which were hospitalized, found 73% had at least 1 persistent symptom for weeks after Covid-19.

COVID Morbidity – The emerging burden of long COVID is significant, and needs to be considered when evaluating the risk vs. benefit of pandemic measures.

One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively

Population-based cohort study: Non-hospitalized COVID-19 patients have low-risk of serious long-term effects, but visits to general practitioners and outpatient hospital visits are increased.

One third of patients hospitalized with COVID-19 have lung changes after a year

Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

Long Covid Implications for the workplace

Long Covid in the UK – More than a million affected in February, survey suggests

Covid-19: Middle aged women face greater risk of debilitating long term symptoms

Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”

Opinion | We need to start thinking more critically — and speaking more cautiously — about long Covid

Review | Post-acute COVID-19 syndrome

Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19

Perspective | Long Covid isn’t as unique as we thought

Attributes and predictors of long COVID

WHO Report: Preparing for Long COVID 2021

Long Covid: Sequelae in adults at 6 Months after COVID-19 infection

How many people get ‘long COVID’ – and who is most at risk?

Long Covid: Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Patients, clinicians seek answers to the mystery of ‘Long COVID’

Long Covid: 6-month consequences of COVID-19 in patients discharged from hospital

[Preprint] Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact

NICE Guideline: Managing the long-term effects of COVID-19

 

Commentary on Twitter

https://twitter.com/svillapol/status/1425032774793285648

 

Opinion | We should not dismiss the possibility of eradicating COVID-19: comparisons with smallpox and polio.

11 Aug, 2021 | 08:42h | UTC

We should not dismiss the possibility of eradicating COVID-19: comparisons with smallpox and polio – BMJ Global Health

News release: Global eradication of COVID-19 probably feasible, and more so than for polio, say public health experts – British Medical Journal

 

CDC Report: COVID-19 morbidity and mortality far exceed the potential risks of rare side effects caused by vaccines.

11 Aug, 2021 | 08:45h | UTC

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 – CDC Morbidity and Mortality Weekly Report

 

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

11 Aug, 2021 | 08:44h | UTC

Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review – JAMA Cardiology

Related:

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Commentary on Twitter

https://twitter.com/JohnGRizk/status/1425126093288353800

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.